Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake
Trust the labeled amount from reputable suppliers and focus on proper reconstitution technique
Mechanistic confirmation using pathway-specific inhibitors or genetic models will be essential in future work to delineate the specific molecular targets underlying SPAEs protective actions
Results did not change when restricting the analysis to patients with NAFLD at baseline (15 patients in the liraglutide group, 16 in the sitagliptin group, and 15 in the placebo group) [76]
To view a copy of this licence, visit About this article Cite this article Mastaitis, J.W., Gomez, D., Raya, J.G
However, glucagon agonism also comes with its own side effects and considerations